{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:11:36Z","timestamp":1792541496943,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.04.019","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T14:38:38Z","timestamp":1621348718000},"page":"390-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014\u20132018 studies in Italy"],"prefix":"10.1016","volume":"25","author":[{"given":"Stefano","family":"Stracquadanio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Santerre","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.04.019_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.019_bib0002","series-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","year":"2017"},{"key":"10.1016\/j.jgar.2021.04.019_bib0003","series-title":"Antibiotic resistance threats in the United States 2019","year":"2019"},{"key":"10.1016\/j.jgar.2021.04.019_bib0004","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.5.1800159","article-title":"Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017","volume":"24","author":"Iacchini","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.019_bib0005","series-title":"Surveillance of antimicrobial resistance in Europe 2018","year":"2019"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.019_bib0006","first-page":"52","article-title":"Antibiotic resistance: where are we going?","volume":"30","author":"La Fauci","year":"2018","journal-title":"Ann Ig"},{"key":"10.1016\/j.jgar.2021.04.019_bib0007","series-title":"ECDC country visit to Italy to discuss antimicrobial resistance issues. 9\u201313 January 2017","year":"2017"},{"key":"10.1016\/j.jgar.2021.04.019_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.meegid.2014.11.025","article-title":"Evaluation of carbapenem-resistant Enterobacteriaceae in an Italian setting: report from the trench","volume":"30","author":"Barbarini","year":"2015","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jgar.2021.04.019_bib0009","doi-asserted-by":"crossref","first-page":"20489","DOI":"10.2807\/ese.18.22.20489-en","article-title":"Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011","volume":"18","author":"Giani","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.019_bib0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","article-title":"A review on colistin nephrotoxicity","volume":"71","author":"Ordooei Javan","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.04.019_bib0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11908-018-0617-x","article-title":"The epidemiology, evolution, and treatment of KPC-producing organisms","volume":"20","author":"Porreca","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jgar.2021.04.019_bib0012","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","article-title":"Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria","volume":"5","author":"Olaitan","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.04.019_bib0013","series-title":"Fetcroja (cefiderocol) summary of product characteristics","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.019_bib0014","series-title":"Fetroja (cefiderocol) prescribing information","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.019_bib0015","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.019_bib0016","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.019_bib0017","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.019_bib0018","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.019_bib0019","doi-asserted-by":"crossref","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.019_bib0020","year":"2019"},{"key":"10.1016\/j.jgar.2021.04.019_bib0021","series-title":"Guidance document on broth microdilution testing of cefiderocol","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.019_bib0022","doi-asserted-by":"crossref","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.019_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.019_bib0024","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.019_bib0025","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021","year":"2021"},{"key":"10.1016\/j.jgar.2021.04.019_bib0026","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.04.019_bib0027","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.019_bib0028","series-title":"Cefiderocol injection \u2013 FDA identified breakpoints","year":"2020"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2021.04.019_bib0029","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.019_bib0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.6.2000085","article-title":"Prolonged outbreak of New Delhi metallo-\u03b2-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019","volume":"25","author":"Tavoschi","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.019_bib0031","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem\u2013cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.019_bib0032","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.019_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jgar.2018.11.027","article-title":"Epidemiological investigation of anAcinetobacter baumannii outbreak using core genome multilocus sequence typing","volume":"17","author":"Venditti","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.019_bib0034","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in ICU patients","author":"Falcone","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:57:15Z","timestamp":1761991035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521001181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S2213716521001181"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.019","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014\u20132018 studies in Italy","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}